Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

PURPOSE To evaluate the safety, tolerance, and hematologic effects of recombinant human interleukin-3 (IL-3) in patients with small-cell lung cancer (SCLC) before and following multiagent antineoplastic therapy in a placebo-controlled, randomized, double-blind study. PATIENTS AND METHODS Twenty-eight patients (22 men and six women; median age, 60 years) with previously untreated SCLC entered the study. Patients were assigned to six groups of escalating-dose IL-3 ranging from 0.25 to 10 micrograms/kg/d administered by continuous infusion for 7 days, with one patient in each group receiving placebo. After a 1-week interval, the first of three cycles of carboplatin, etoposide (VP16), and epirubicin (CVE) given every 3 weeks was administered. The second cycle of CVE was followed by 7 days of IL-3 administered at the same daily dose as administered during the first infusion. RESULTS The maximum-tolerated dose was not encountered in this study. Fever was the most frequently observed side effect. Before any chemotherapy, World Health Organization (WHO) grade II fever only appeared at doses > or = 2.5 micrograms/kg/d. Other side effects included rash, headache, and myalgia. During the first infusion of IL-3, before administration of chemotherapy, dose-dependent increases in peripheral-platelet counts (r = .613; P < .001) and neutrophil counts (r = .505; P = .007) were observed. Following the second cycle of CVE, recovery of peripheral platelet counts was faster as compared with the first cycle of CVE for patients treated with 7.5 and 10 micrograms/kg of IL-3 (P = .021). Chemotherapy postponements due to myelotoxicity were also less frequent following the second cycle of CVE as compared with the first for patients treated with > or = 2.5 micrograms/kg of IL-3 (P = .036). Compared with an age-matched historical group receiving identical chemotherapy (n = 191), administration of IL-3 did not modify either disease-free survival or overall patient survival rates. CONCLUSION IL-3 is well tolerated at doses up to 10 micrograms/kg/d. In the absence of chemotherapy, biologic effects on both neutrophils and platelets were seen at doses > or = 2.5 micrograms/kg/d. IL-3 infusion following the second cycle of CVE appears to reduce chemotherapy-induced myelosuppression, but does not alter tumor response or patient survival rates.

[1]  D. Rubinstein,et al.  Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. , 1993, Cancer research.

[2]  M. Collins,et al.  Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents , 1992, The Journal of experimental medicine.

[3]  de Elisabeth G. E. Vries,et al.  Effects of interleukin-3 after chemotherapy for advanced ovarian cancer , 1992 .

[4]  E. Vellenga,et al.  Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Ganser,et al.  Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. , 1992, Blood.

[6]  A. Ganser,et al.  Biologic effects of recombinant human interleukin-3 in vivo. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Hoffman,et al.  Effect of c-kit ligand on in vitro human megakaryocytopoiesis. , 1991, Blood.

[8]  M. Ro̸rth,et al.  Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours , 1991, The Lancet.

[9]  Z. Estrov,et al.  Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Hoffman,et al.  Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. , 1991, Experimental hematology.

[11]  C. Meyer,et al.  The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of the eleven cell lines. , 1991, Cancer research.

[12]  A. Ganser,et al.  Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. , 1990, Blood.

[13]  A. Ganser,et al.  Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. , 1990, Blood.

[14]  A. Ganser,et al.  Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. , 1990, Blood.

[15]  J. Singer,et al.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. , 1990, Blood.

[16]  P. Valent,et al.  Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates--synergism with recombinant human granulocyte/macrophage colony-stimulating factor. , 1990, Blood.

[17]  F. Herrmann,et al.  Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. , 1990, The American journal of medicine.

[18]  J. Laver,et al.  Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. , 1990, The Journal of clinical investigation.

[19]  F. Pettersson,et al.  Leukemia following chemotherapy for ovarian cancer , 1990 .

[20]  T. Dexter,et al.  Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis , 1990, Nature.

[21]  E. Weinmann,et al.  Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys. , 1990, International journal of cell cloning.

[22]  J. Canon,et al.  Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts. , 1989, Cancer research.

[23]  P. Valent,et al.  The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. , 1989, Blood.

[24]  C. Sieff,et al.  Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. , 1989, Blood.

[25]  F. Seiler,et al.  In vivo effects of recombinant colony stimulating factors on hematopoiesis in cynomolgus monkeys. , 1989, Transplantation proceedings.

[26]  J. Gabrilove,et al.  Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. , 1988, The Journal of clinical investigation.

[27]  P. Sehgal,et al.  Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. , 1988, Science.

[28]  M. Socinski,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.

[29]  Y. Sonoda,et al.  Analysis in serum-free culture of the targets of recombinant human hemopoietic growth factors: interleukin 3 and granulocyte/macrophage-colony-stimulating factor are specific for early developmental stages. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Socinski,et al.  GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN , 1988, The Lancet.

[31]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[32]  J. Machiels,et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[34]  W. Hryniuk,et al.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Uyttenhove,et al.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Johnson,et al.  Acute nonlymphocytic leukemia after treatment of small cell lung cancer. , 1986, The American journal of medicine.

[37]  Clift Ra,et al.  Marrow transplantation for patients with acute nonlymphoblastic leukemia who achieve a first remission. , 1982, Cancer treatment reports.

[38]  H. van den Berghe,et al.  "Spontaneous" erythroid progenitor cells in the circulation and monosomy 7 in juvenile chronic myelogenous leukemia. , 1982, Cancer genetics and cytogenetics.